[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:pre-t-all":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":166,"states":167},"Pre T-ALL",25,21,[8,16,22,29,35,41,47,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,145,152,159],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06561074","A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed\u002FRefractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)",[12],"Phase 2","RECRUITING","2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.027374Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06514794","A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)",[12],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:28.839140Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06934382","Anti-CD7 CAR-T Cells in Relapsed\u002FRefractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma",[26],"Phase 1","2026-08-26T02:16:04.914942Z","2026-05-05T02:43:28.192739Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07513129","Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma",[26],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.944236Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT00501826","Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[12],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:27.590403Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05289687","Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL",[12],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.436614Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT07070219","A Study of CTD402 in T-ALL\u002FLBL Patients",[51],"Phase 1\u002FPhase 2","2026-08-26T02:17:33.002248Z","2026-05-05T02:43:27.056234Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06738368","Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:26.755408Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04972942","Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma",[26],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:26.740242Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT04315324","Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)",[51],"2026-08-26T02:16:07.529922Z","2026-05-05T02:35:31.752200Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07220993","Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells",[26],"2026-08-26T02:15:36.077529Z","2026-05-05T02:43:28.987867Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06390319","Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)",[12],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:28.653429Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT03081910","Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen",[26],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:26.923493Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05110742","Phase I\u002FII Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed\u002FRefractory Hematological Malignances",[51],"2026-08-26T02:18:40.612983Z","2026-07-30T01:46:14.462113Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT04318678","CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",[26],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.730542Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT03826992","Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia",[26],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:29.669276Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[51],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[51],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT04329728","The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",[51],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.628795Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[51],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.847376Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT06904066","Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies",[26],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:27.428326Z",{"nct_id":139,"title":140,"phases":141,"status":142,"updated_at":143,"content_modified":144},"NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.805067Z",{"nct_id":146,"title":147,"phases":148,"status":149,"updated_at":150,"content_modified":151},"NCT05509855","A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:09.452956Z","2026-06-16T05:54:08.033796Z",{"nct_id":153,"title":154,"phases":155,"status":156,"updated_at":157,"content_modified":158},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[26],"ACTIVE_NOT_RECRUITING","2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.128098Z",{"nct_id":160,"title":161,"phases":162,"status":156,"updated_at":164,"content_modified":165},"NCT05602194","Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma",[163],"Phase 3","2026-08-03T02:14:31.240767Z","2026-05-05T02:35:31.762991Z",[],[168,172,176,180,183,187,191,194,197,200,204,207,210,214,217,220,223,226,229,232,235,238],{"state":169,"count":170,"slug":171},"Texas",15,"texas",{"state":173,"count":174,"slug":175},"California",8,"california",{"state":177,"count":178,"slug":179},"Pennsylvania",7,"pennsylvania",{"state":181,"count":178,"slug":182},"Tennessee","tennessee",{"state":184,"count":185,"slug":186},"Ohio",6,"ohio",{"state":188,"count":189,"slug":190},"Colorado",5,"colorado",{"state":192,"count":189,"slug":193},"Florida","florida",{"state":195,"count":189,"slug":196},"Illinois","illinois",{"state":198,"count":189,"slug":199},"Maryland","maryland",{"state":201,"count":202,"slug":203},"Missouri",4,"missouri",{"state":205,"count":202,"slug":206},"New York","new-york",{"state":208,"count":202,"slug":209},"Washington","washington",{"state":211,"count":212,"slug":213},"Arizona",3,"arizona",{"state":215,"count":212,"slug":216},"District of Columbia","district-of-columbia",{"state":218,"count":212,"slug":219},"Georgia","georgia",{"state":221,"count":212,"slug":222},"Kentucky","kentucky",{"state":224,"count":212,"slug":225},"Michigan","michigan",{"state":227,"count":212,"slug":228},"Minnesota","minnesota",{"state":230,"count":212,"slug":231},"Nebraska","nebraska",{"state":233,"count":212,"slug":234},"North Carolina","north-carolina",{"state":236,"count":212,"slug":237},"Virginia","virginia",{"state":239,"count":212,"slug":240},"Wisconsin","wisconsin"]